Novartis Pays $35M To Settle Elidel Marketing False Claims Lawsuit
PHILADELPHIA — Novartis Pharmaceuticals Corp. will pay $35 million to resolve a whistle-blower’s claim that the drug maker marketed Elidel for use with children under 2 and as a first-line drug,...To view the full article, register now.
Already a subscriber? Click here to view full article